FDA Greenlights Trial, Lifting Biocytogen Stock 6.3%
The U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application for NEOK002, an antibody-drug conjugate (ADC) developed by Biocytogen's partner, NEOK Bio. The approval allows the company to proceed with clinical trials for the drug, which targets solid tumors. News of the regulatory clearance prompted a positive market reaction, with shares of Biocytogen (02315.HK) climbing 6.32%.
NEOK002 is specifically designed as an ADC targeting EGFR/MUC1, a bispecific approach intended to offer greater efficacy and an improved safety profile compared to single-target therapies. This approval represents a significant de-risking event for the drug's development path and provides a tangible validation of Biocytogen's underlying technology.
NEOK002 Phase I Trial Set for Q2 2026
NEOK Bio is preparing to initiate a Phase I clinical trial for NEOK002 in the second quarter of 2026. The company anticipates releasing preliminary data from this initial human study in 2027. The drug candidate is built upon a bispecific antibody that was originally developed using Biocytogen's proprietary platform and licensed to NEOK Bio in 2024.
The IND clearance is a critical step forward, marking the transition from preclinical research to human trials. Success in these upcoming phases could position NEOK002 as a differentiated treatment for patients with various solid tumors, a field with significant unmet medical need.
Approval Validates Biocytogen's Discovery Platform
This regulatory milestone serves as a key validation for Biocytogen's business model, which focuses on developing novel antibody-based drug candidates and licensing them to partners for further development and commercialization. The antibody in NEOK002 was discovered using Biocytogen's RenLite® platform, which is designed to generate fully human bispecific antibodies.
We are pleased to see one of our partnered molecules reach this important stage of development. This milestone further validates the quality, developability, and therapeutic potential of fully human bispecific antibodies discovered using our RenLite® platform.
— Dr. Yuelei Shen, President and CEO of Biocytogen.
The company has established over 350 similar agreements for its therapeutic antibodies, and the progress of NEOK002 reinforces the value of its extensive discovery pipeline and partnership-driven strategy.
